 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
35 News |  |
- | MB-102 / Fortress
Journal, CAR T-Cell Therapy: Bispecific CD33/CD123 targeted chimeric antigen receptor T (Pubmed Central) - Dec 11, 2023
The CD33/CD123 bispecific CAR T
- | MB-102 / Fortress
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. (clinicaltrials.gov) - Jun 22, 2023
P1/2, N=3, Terminated, Sponsor: Mustang Bio
The CD33/CD123 bispecific CAR T N=44 --> 3 | Trial completion date: Apr 2026 --> May 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2026 --> May 2023; Business reasons.
- anti-CD33 CAR T / City of Hope, National Cancer Institute
CD33 CAR T Cells Generated by Restrained TCR Stimulation and Optimized Cytokines Manifested Potent Antileukemic Activity and Less-Differentiated Memory Phenotype (Board No. 1666) - Apr 6, 2023 - Abstract #ASGCT2023ASGCT_898;
Our previous clinical trial of CD123 CAR T cells was promising but identified the need for a faster CAR T cell manufacturing process. Using a combination of restrained TCR stimulation (4D-2:1 bead) and IL2/IL15 cytokines, we optimized our CD33 CAR T cell production platform to yield highly proliferative CAR T cells with less-differentiated memory phenotype and potent antigen-dependent antileukemic efficacy.
- | MB-102 / Fortress
Trial primary completion date: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. (clinicaltrials.gov) - Mar 13, 2023
P1/2, N=44, Recruiting, Sponsor: Mustang Bio
Using a combination of restrained TCR stimulation (4D-2:1 bead) and IL2/IL15 cytokines, we optimized our CD33 CAR T cell production platform to yield highly proliferative CAR T cells with less-differentiated memory phenotype and potent antigen-dependent antileukemic efficacy. Trial primary completion date: Mar 2023 --> Mar 2026
- MB-102 / Fortress, Istodax (romidepsin) / Astellas, BMS
Significantly Targeting Acute Myeloid Leukemia with the Combination of Anti-CD123 CAR Modified Expanded Natural Killer Cells and Romidepsin () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_868;
Results Anti-CD123 CAR expressed on more than 96% of expanded NK cells after CAR mRNA electroporation (Fig.1A) and lasted for about one week. Anti-CD123 CAR NK showed significantly enhanced in vitro cytotoxicity against CD123 + KG1a and HL-60 with significantly enhanced IFN-
- |||||| MB-102 / Fortress, MB-106 / Fortress
New trial, CAR T-Cell Therapy: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. (clinicaltrials.gov) - Dec 9, 2022
P=N/A, N=331, Enrolling by invitation, Sponsor: Mustang Bio
- ||| MB-102 / Fortress
Enrollment change: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. (clinicaltrials.gov) - Feb 15, 2021
P1/2, N=44, Recruiting, Sponsor: Mustang Bio
Anti-CD123 CAR NK showed significantly enhanced in vitro cytotoxicity against CD123 + KG1a and HL-60 with significantly enhanced IFN- N=126 --> 44
- || MB-102 / Fortress
Trial initiation date: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. (clinicaltrials.gov) - Feb 17, 2020
P1/2, N=126, Recruiting, Sponsor: Mustang Bio
N=126 --> 44 Initiation date: Sep 2019 --> Feb 2020
- | MB-102 / Fortress
New P1/2 trial: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. (clinicaltrials.gov) - Sep 29, 2019
P1/2, N=126, Recruiting, Sponsor: Mustang Bio